1380PDEfficacy of lorlatinib in patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC) and ROS1 kinase domain mutations. (23rd October 2018) - Solomon, B J; Martini, J-F; Ou, S-H I; Chiari, R; Soo, R A; Bearz, A; Li, S; Thurm, H; Lin, C-C; Riely, G J; Bauer, T M; Shaw, A T